Ernesto Estrada, Samuel Vazquez, Jul 28, 2013
This document studies bid rigging in public procurement of generic drugs in Mexico. The study is based on the outcomes of a series of public auctions for generic drugs held in 52 different locations between 2003 and 2008. By applying price and market share screenings, we identify many drugs where lowest bids tend to be identical across auctions regardless of winner, location or contract volume; and market shares quickly converge over time. Additionally, bids dropped and the above pattern disappeared after aggressive entry or procurement consolidation occurred. These findings triggered a formal investigation by the Mexican antitrust agency of two of the largest families of drugs: insulin and saline solutions. These collusive patterns and other indirect evidence gathered during the investigation, led to issue a decision by the agency of illegal bid rigging in both cases. This decision was challenged before Mexican courts, which confirmed it.
Featured News
Carey Bolsters Competition Law Team With New Senior Counsel
Mar 15, 2026 by
CPI
TikTok US Sale Could Deliver $10 Billion Windfall to the United States
Mar 15, 2026 by
CPI
States Press Ahead With Live Nation Antitrust Trial After Federal Settlement
Mar 15, 2026 by
CPI
US Pulls Back Draft Regulation Targeting Global AI Chip Shipments
Mar 15, 2026 by
CPI
Selecta and Bondholders Ask US Court to Dismiss Antitrust Lawsuit Over Creditor Pact
Mar 15, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece